Sicor
Executive Summary
Company has reached a settlement with Protocol Systems regarding the drug delivery device GenESA. Marketing plans for GenESA, which delivers arbutamine to patients with suspected coronary artery disease, were abandoned after the company assessed that marketing costs would be prohibitive. Protocol had entered an agreement with Gensia Automedics to provide a component of the device, and sued in 1998 to recoup its losses. The original suit was filed for $10 mil. The settlement is less than $3.7 mil. and will be paid over a few years, Sicor said